Skip to content
Open access · CC-BY via OpenAlex

Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons

Krish Chandrasekaran, Joungil Choi, Muhammed Ikbal Arvas, Mohammad Salimian, Sujal Singh, Su Xu, Rao P. Gullapalli, Tibor Kristián, James W. Russell

International Journal of Molecular Sciences · 2020 · ▲ 83 citations

Abstract

Diabetes predisposes to cognitive decline leading to dementia and is associated with decreased brain NAD+ levels. This has triggered an intense interest in boosting nicotinamide adenine dinucleotide (NAD+) levels to prevent dementia. We tested if the administration of the precursor of NAD+, nicotinamide mononucleotide (NMN), can prevent diabetes-induced memory deficits. Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ). After 3 months of diabetes, hippocampal NAD+ levels were decreased (p = 0.011). In vivo localized high-resolution proton magnetic resonance spectroscopy (MRS) of the hippocampus showed an increase in the levels of glucose (p < 0.001), glutamate (p < 0.001), gamma aminobutyric acid (p = 0.018), myo-inositol (p = 0.018), and taurine (p < 0.001) and decreased levels of N-acetyl aspartate (p = 0.002) and glutathione (p < 0.001). There was a significant decrease in hippocampal CA1 neuronal volume (p < 0.001) and neuronal number (p < 0.001) in the Diabetic rats. Diabetic rats showed hippocampal related memory deficits. Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months. NMN increased brain NAD+ levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione. NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control. In hippocampal protein extracts from Diabetic rats, SIRT1 and PGC-1α protein levels were decreased, and acetylation of proteins increased. NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins. Our results indicate that NMN increased brain NAD+, activated the SIRT1 pathway, preserved mitochondrial oxidative phosphorylation (OXPHOS) function, prevented neuronal loss, and preserved cognition in Diabetic rats.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3390/ijms21113756
Canonical
link ↗
Fetched
2026-06-16 MST

Cite this

APA
Chandrasekaran, K., Choi, J., Arvas, M.I., Salimian, M., Singh, S., Xu, S., Gullapalli, R.P., Kristián, T., &amp; Russell, J.W. (2020). Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons. <em>International Journal of Molecular Sciences</em>. https://doi.org/10.3390/ijms21113756
Vancouver
Chandrasekaran K, Choi J, Arvas MI, Salimian M, Singh S, Xu S, et al. Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons. International Journal of Molecular Sciences. 2020. doi:10.3390/ijms21113756.
BibTeX
@article{krish2020Nicoti, title = {Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons}, author = {Krish Chandrasekaran and Joungil Choi and Muhammed Ikbal Arvas and Mohammad Salimian and Sujal Singh and Su Xu and Rao P. Gullapalli and Tibor Kristián and James W. Russell}, journal = {International Journal of Molecular Sciences}, year = {2020}, doi = {10.3390/ijms21113756}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings